Advances of VEGF signalling pathway in hepatocellular carcinomar in-vasion and metastasis and therapy
10.12092/j.issn.1009-2501.2024.05.013
- VernacularTitle:抗VEGF及其受体分子靶向药物治疗肝癌机制的研究进展
- Author:
Xueling LAN
1
;
Yanni HUANG
;
Minmin ZHU
;
Ping MA
;
Min DONG
Author Information
1. 广西医科大学药学院,南宁 530021,广西
- Keywords:
VEGF/VEGFR inhibitors;
hepatocellu-lar carcinoma;
signalling pathway;
immunotherapy
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(6):707-714
- CountryChina
- Language:Chinese
-
Abstract:
ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.
